Conscience launches to tackle drug discovery and development for diseases sidelined by pharmaceutical science
TORONTO (5 October 2023) – Conscience, a game-changing non-profit venture focused on enabling drug discoveries for diseases that have received limited attention from the pharmaceutical industry, launched today with pioneering support from the Canadian government.
With CA$105.7 million in funding, including $49 million from the Canadian government and the engagement of industry, academia, government and patient advocacy groups, Conscience seeks to lead global drug discovery and development for emerging, rare or complex ...









